Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1498 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Jean Bousquet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berl…. Hauptthemen laut MEDLINE: Phthalazines. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration–time curve from time zero to the last measurable concentration. This was a Phase 1, open‐label, single‐center, randomized, parallel‐group study. Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C. Maximum plasma concentration and area under the plasma concentration–time curve were similar when compared in treatments A and C (0.1%) for AZE and its metabolite, desmethylazelastine. The most frequently reported adverse events were rhinorrhea (5.6%) and sneezing (5.6%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.
- Center for Rhinology and Allergology, Wiesbaden, Hessen, Germany.
- Global Clinical Pharmacology, Mylan Pharmaceuticals Inc. (Now Viatris), Canonsburg, PA, USA.
- Global Clinical Sciences, MEDA Pharma GmbH & Co KG (A Viatris Company), Bad Homburg, Hessen, Germany.
- Mylan Pharmaceuticals Private Limited (Now Viatris), Bengaluru, India.
Zitieren
APA
Bousquet, J., Klimek, L., Liu, M., Nguyen, D. T., Ramalingam, R. K., Canonica, G. W., & Berger, W. E. (2025). Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1498
Vancouver
Bousquet J, Klimek L, Liu M, Nguyen DT, Ramalingam RK, Canonica GW, et al. Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1498
BibTeX
@article{Bousquet2025,
author = {Bousquet, Jean and Klimek, Ludger and Liu, Mark and Nguyen, Duc Tung and Ramalingam, Rajesh Kumar and Canonica, Georgio Walter and Berger, William E},
title = {Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1498}
}
EUVIMED